Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets
Alvotech entered a strategic licensing and commercialization agreement with Lotus Pharmaceutical for its biosimilar candidates AVT34 and AVT87, referencing Imfinzi and Hemlibra respectively. Under the terms, Alvotech retains semi-exclusive rights to commercialize both products in the United States for the first time, while Lotus holds exclusive rights in eight selected Asian markets including South Korea and Taiwan.
Key figures
- Deal Value Usd
- 150000000
- Imfinzi sales 2025
- $6.1 billion
- Asian markets count
- 8
- Hemlibra sales 2025 usd
- $5.8 billion
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.